KR20240148324A - 유해 약물 상호작용 및 효과를 피하기 위한 우파다시티닙의 투여 방법 - Google Patents

유해 약물 상호작용 및 효과를 피하기 위한 우파다시티닙의 투여 방법 Download PDF

Info

Publication number
KR20240148324A
KR20240148324A KR1020247024707A KR20247024707A KR20240148324A KR 20240148324 A KR20240148324 A KR 20240148324A KR 1020247024707 A KR1020247024707 A KR 1020247024707A KR 20247024707 A KR20247024707 A KR 20247024707A KR 20240148324 A KR20240148324 A KR 20240148324A
Authority
KR
South Korea
Prior art keywords
upadacitinib
dose
patient
daily
patients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247024707A
Other languages
English (en)
Korean (ko)
Inventor
모하메드-에슬람 에프. 모하메드
Original Assignee
애브비 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 애브비 인코포레이티드 filed Critical 애브비 인코포레이티드
Publication of KR20240148324A publication Critical patent/KR20240148324A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020247024707A 2022-01-13 2023-01-13 유해 약물 상호작용 및 효과를 피하기 위한 우파다시티닙의 투여 방법 Pending KR20240148324A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263299324P 2022-01-13 2022-01-13
US63/299,324 2022-01-13
US202263320149P 2022-03-15 2022-03-15
US63/320,149 2022-03-15
PCT/US2023/060648 WO2023137440A2 (en) 2022-01-13 2023-01-13 Method of administering upadacitinib to avoid adverse drug interactions and effects

Publications (1)

Publication Number Publication Date
KR20240148324A true KR20240148324A (ko) 2024-10-11

Family

ID=87279802

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247024707A Pending KR20240148324A (ko) 2022-01-13 2023-01-13 유해 약물 상호작용 및 효과를 피하기 위한 우파다시티닙의 투여 방법

Country Status (8)

Country Link
US (1) US20230233555A1 (https=)
EP (1) EP4463161A4 (https=)
JP (1) JP2025502266A (https=)
KR (1) KR20240148324A (https=)
AU (1) AU2023206381A1 (https=)
CA (1) CA3246767A1 (https=)
MX (1) MX2024008557A (https=)
WO (1) WO2023137440A2 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12570664B2 (en) 2015-10-16 2026-03-10 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-α]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US12365689B2 (en) 2015-10-16 2025-07-22 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
SG10201913990RA (en) 2015-10-16 2020-03-30 Abbvie Inc PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11564922B2 (en) * 2017-03-09 2023-01-31 Abbvie Inc. Methods of treating crohn's disease and ulcerative colitis
AU2018230500B2 (en) * 2017-03-09 2024-03-07 Abbvie Inc. Methods of treating Crohn's disease and ulcerative colitis
US10857144B2 (en) * 2017-05-16 2020-12-08 Bow River LLC Methods of treatment

Also Published As

Publication number Publication date
WO2023137440A3 (en) 2023-10-05
AU2023206381A1 (en) 2024-07-25
EP4463161A2 (en) 2024-11-20
EP4463161A4 (en) 2026-01-14
MX2024008557A (es) 2024-09-11
CA3246767A1 (en) 2023-07-20
JP2025502266A (ja) 2025-01-24
US20230233555A1 (en) 2023-07-27
WO2023137440A2 (en) 2023-07-20

Similar Documents

Publication Publication Date Title
KR20240148324A (ko) 유해 약물 상호작용 및 효과를 피하기 위한 우파다시티닙의 투여 방법
AU2018210397B2 (en) Combinations of cabozantinib and atezolizumab to treat cancer
KR20200070334A (ko) 비-전이성 거세-저항성 전립선암의 치료를 위한 항-안드로겐
TW202142229A (zh) 治療雷葛氏症候群之病患的方法
US8957071B2 (en) Treatment of vascular, autoimmune and inflammatory diseases using low dosages of IMPDH inhibitors
JP2018118914A (ja) 神経変性疾患の改善用医薬
KR20220157313A (ko) 타우로데옥시콜린산 또는 이의 약학적으로 허용가능한 염을 유효성분으로 함유하는 코로나바이러스감염증-19(covid-19) 치료용 조성물
JP2023522623A (ja) 全身性過炎症反応を伴う状態の処置に使用するエクリタセルチブ
KR20210034623A (ko) 다발성 경화증의 치료 및 예방을 위한 방법에서 사용하기 위한 치환된 아미노-피리미딘 화합물
Chen et al. Drug-drug interaction between paxlovid and tacrolimus in a patient with myasthenia gravis and SARS-CoV-2 infection
TW202421141A (zh) 用於多發性硬化症及重症肌無力之治療性酪胺酸激酶抑制劑
AM et al. Full prescribing information
KR20200021479A (ko) 페마피브레이트를 함유하는 의약
CN118891046A (zh) 施用乌帕替尼以避免不良药物相互作用和反应的方法
JP6042886B2 (ja) 早漏症治療用の薬学組成物
CN114984017A (zh) 用于中枢神经系统脱髓鞘疾病治疗的化合物
AB Summary of product characteristics
CA3161761A1 (en) Methods of administering voxelotor
US12409172B2 (en) Dosage regimen
WO2025235366A1 (en) Pyrrolopyrimidine compositions for treatment of atopic dermatitis
Alkanat et al. Dermatologic Reactions Following COVID-19 Vaccination: A Case Series
Dihydrochloride AHFS® firstRelease™
KR20250084183A (ko) 다발성 경화증에 대한 치료용 티로신 키나제 저해제
Venkitakrishnan et al. Drug Corner Baricitinib: Delineating a New Treatment Option in COVID-19
JP2025509615A (ja) 汗腺炎を治療するための方法、投与計画、および組成物

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000